A case of severe dermatitis in a patient with Polycythemia Vera during cytoreductive therapy by Accurso Vincenzo, Santoro Marco, Caputo Valentina, Fiorella Santi, Casimiro Paolo, Sardio Mariano, Marino Carla, Sucato Giuseppe, Siragusa Sergio
020
Citation: Accurso V, Santoro M, Caputo V, Fiorella S, Casimiro P, et al. (2019) A case of severe dermatitis in a patient with Polycythemia Vera during cytoreductive 














Polycythemia Vera (PV) is a Philadelphia-negative chronic myeloproliferative neoplasm (MPN) mainly 
characterized by erythrocytosis. In this report we describe a case of severe cutaneous toxicity in patients 
with PV treated with hydroxyurea. A 72-year-old woman diagnosed with PV with V617F mutation of JAK2 
performed more than 10 years before and treated with hydroxyurea plus phlebotomies and low-dose ASA 
for about 7 years addressed our center for the appearance of serious dermatitis at the face symptomatic 
for severe itch. The patient underwent a dermatology visit with diagnosis of desquamative dermatitis due 
to iatrogenic cause related to the use of hydroxyurea. HU was stopped for a month with no improvement 
after a month of wash-out. Ruxolitinib was prescribed at a dose of 20 mg per day, in order to control 
hypercytosis and considering the severe intolerance to hydroxyurea. Ruxolitinib allowed not only to 
reduce the haematocrit, reaching the target value of 45%, and control thrombocytosis, but also to switch 
off the severe itch and to completely resolve skin toxicity.
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Polycythemia Vera (PV) is a Philadelphia-negative chronic 
myeloproliferative neoplasm (MPN) mainly characterized by 
erythrocytosis. Other disease features include leukocytosis, 
splenomegaly, micro-circulatory symptoms, itch, thrombotic 
and hemorrhagic risk and possible leukemic or fi brotic 
evolution. Diagnosis of PV is currently put according to the 2016 
WHO criteria and is based on a composite assessment of clinical 
and laboratory features [1,2]. The presence of V617F JAK2 
mutation on exon 14 is expected in more than 95% of patients 
with PV while 2-3% of patients with PV harbor a mutation 
on the exon 12 of the same gene [3]. The use of low-dose of 
aminosalicylic acid and phlebotomy to a hematocrit target of 
45% is recommended in all patients with low risk PV. High-
risk patients with PV should receive hydroxyurea in addition 
to ASA low-dose, as fi rst-line cytoreductive drug of choice, in 
order to minimize the risk of thrombosis [4]. In this report we 
describe a case of severe cutaneous toxicity in patients with PV 
treated with hydroxyurea. This case description was approved 
by our hospital’s ethics committee and the necessary permits 
were obtained from the patient.
Case Report
A 72-year-old woman diagnosed with PV with V617F 
mutation of JAK2 performed more than 10 years before and 
treated with hydroxyurea plus phlebotomies and low-dose 
ASA for about 7 years addressed our center for the appearance 
of serious dermatitis at the face symptomatic for severe itch 
(Figure 1A). The cutaneous changes, localized on front, cheeks, 
perioral region and auricles, were characterized by brightly 
red erythematous patches and papular lesions with irregular 
contours, gradually fading toward the normal skin. After seven 
days, clinical features included a diffuse facial erythrodermatous 
eruption with fi ne desquamation, slight periorbital edema and 
cheilitis. There wasn’t evidence of blistering or pustulation. 
The patient complained for itch and burning pain. Mucous 
membrane involvement was absent. A Complete Blood Count 
showed white blood cells (WBC) = 10’550/mcl, red blood cells 
(RBC) = 4’500’000/mcl with hemoglobin (HGB) = 13.5 g/dl, 
hematocrit (HCT) = 43.5% and platelets (PLT) = 450’000/mcl. 
The patient underwent a dermatology visit with diagnosis 
of desquamative dermatitis due to iatrogenic cause related 
to the use of hydroxyurea. Withdrawal of hydroxyurea was 
advised and topical and systemic glucocorticoids (Prednisone 
25 mg once a day) were prescribed. One month after stopping 
hydroxyurea therapy, the symptoms had not regressed and 
laboratory tests showed an increase in HCT (48%), HGB (16.8 
g/dl), PLT (1’234’000/mcl) and WBC (20’200/mcl.). The severe 
itching altered the patient’s quality of life. Based on laboratory 
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tests and symptoms, Ruxolitinib was prescribed at a dose of 20 
mg per day, in order to control hypercytosis and considering 
the severe intolerance to hydroxyurea. At the next check-up, 
after just one month of ruxlitinib therapy, the clinical situation 
was signifi cantly improved with complete regression of 
dermatitis (Figure 1B) and marked improvement in laboratory 
values was obtained (HCT 44.5%, HGB 14.2 g/dl, PLT 650,000/
mcl and WBC 14,500/mcl). The patient is still taking Ruxolitinib 
regularly with good platelet and hematocrit control. 
Discussion and Conclusions
Hydroxyurea is an antimetabolite agent used in the 
treatment of myeloproliferative disorders and sickle cell 
disease. The most common side effects of HU are mild, 
and include granulocytopenia and anemia, especially after 
long-term treatment. Other common side effects include 
fatigue, headache, nausea, vomiting, diarrhea, or fever that 
seldom cause discontinuation of the drug. The occurrence 
of painful leg ulcers is a rare complication that has been 
described in patients receiving high-dose long-term HU 
treatment, often leading to drug discontinuation or dose 
reduction and consequent lack of effi cacy [5]. In addition to 
skin ulcers, several other mucocutaneous alterations have 
been reported during treatment with HU, ranging from very 
mild (hyperpigmentation, nail discoloration, alopecia, and 
scaling) to severe and uncomfortable toxicities (oral aphtosis, 
dermatomyositis-like eruptions). However, to our knowledge, 
complete and exhaustive descriptions of these skin toxicities 
other than leg ulcers are still lacking in literature [6]. Patients 
exposed to HU (median 3 years) had a risk of second cancer 
similar to unexposed patients (OR 1.06, 95% CI 0.82-1.38). In 
contrast, in cancer-specifi c stratifi ed multivariable analysis, 
HU had two-fold higher risk of developing non-melanoma 
skin cancer (OR = 2,28, 95% CI1.15-4.51) [7]. In the pivotal 
RESPONSE study, Ruxolitinib, a Janus Kinase (JAK)-1 and -2 
inhibitor, was superior to best available therapy at controlling 
haematocrit and improving splenomegaly and symptoms 
in patients with PV with splenomegaly, who were often 
inadequately controlled with hydroxyurea [8]. Compared 
best available therapy ruxolitinib provides incremental and 
signifi cant improvement of PV related symptoms. Dramatic 
improvements were observed for tiredness, itching, night 
sweats and sweats while awake [9]. Ruxolitinib has also been 
shown to reduce the infl ammatory state sustained by the 
release of various cytokines that lead to a picture of onco-
infl ammation in myeloproliferative diseases [10].
In the case we present in this report, the association between 
cutaneous toxicity and HU therapy was very likely, according to 
the scientifi c literature data, but the drug withdrawal did not 
achieve any benefi t in the short term. On the contrary, therapy 
with Ruxolitinib allowed not only to reduce the haematocrit, 
reaching the target value of 45%, and control thrombocytosis, 
but also to switch off the severe itch and to completely resolve 
skin toxicity.
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Figure 1: A. Clinical presentation of severe desquamative dermatitis in a PV patient 
assuming HU. 
B. Resolution of dermatitis after one month of Ruxolitinib treatment.
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